论文部分内容阅读
目的探讨肿瘤标志物CEA、CA125、NSE和CYFRA21-1的联合检测在肺癌诊断及鉴别诊断中的临床意义。方法检测88例肺癌患者和62例肺良性疾病患者血清CEA、CA125、NSE和CYFRA21-1水平并比较分析。结果肺癌患者CEA、CA125、NSE和CYFRA21-1水平高于良性疾病患者(P<0.05);四项联检的敏感性和特异性最高,明显优于四种肿瘤标志物的单项测定。结论 CEA、CA125、NSE和CYFRA21-1对肺癌诊断均可作为肺癌筛查的指标;四项联合检测可提高肺癌诊断的灵敏度和准确率。
Objective To explore the clinical significance of combined detection of tumor markers CEA, CA125, NSE and CYFRA21-1 in the diagnosis and differential diagnosis of lung cancer. Methods The serum levels of CEA, CA125, NSE and CYFRA21-1 in 88 patients with lung cancer and 62 patients with benign lung disease were detected and compared. Results The levels of CEA, CA125, NSE and CYFRA21-1 in patients with lung cancer were significantly higher than those in patients with benign diseases (P <0.05). The sensitivity and specificity of the four tests were the highest, significantly better than those of the four tumor markers. Conclusions The diagnosis of lung cancer by CEA, CA125, NSE and CYFRA21-1 can all be used as indicators of lung cancer screening. The four combined tests can improve the sensitivity and accuracy of lung cancer diagnosis.